doxapram has been researched along with Plague in 1 studies
Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.
Plague: An acute infectious disease caused by YERSINIA PESTIS that affects humans, wild rodents, and their ectoparasites. This condition persists due to its firm entrenchment in sylvatic rodent-flea ecosystems throughout the world. Bubonic plague is the most common form.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A total of 17 prioritized drugs, based on efficacy in in vitro screens, were chosen for further evaluation in a murine model of pneumonic plague to delineate if in vitro efficacy could be translated in vivo Three drugs, doxapram (DXP), amoxapine (AXPN), and trifluoperazine (TFP), increased animal survivability despite not exhibiting any direct bacteriostatic or bactericidal effect on Y." | 3.83 | New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria. ( Andersson, JA; Chauhan, S; Chopra, AK; Dann, SM; Fitts, EC; Kirtley, ML; Motin, VL; Peniche, AG; Ponnusamy, D; Rosenzweig, JA; Sha, J, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andersson, JA | 1 |
| Fitts, EC | 1 |
| Kirtley, ML | 1 |
| Ponnusamy, D | 1 |
| Peniche, AG | 1 |
| Dann, SM | 1 |
| Motin, VL | 1 |
| Chauhan, S | 1 |
| Rosenzweig, JA | 1 |
| Sha, J | 1 |
| Chopra, AK | 1 |
1 other study available for doxapram and Plague
| Article | Year |
|---|---|
New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria.
Topics: Amoxapine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Survival; Clostridioides difficile | 2016 |